Developer docs
API playgroundTry for free, no card

Search company profiles

GENTAG

Full company profile

uuid000kyl9

Namestring
GENTAG
Legal namestring
GENTAG, Inc.
Websiteurl
gentag.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

GENTAG is a privately held US intellectual-property and technology development company based in Washington, D.C., founded in 1997 by John Peeters, Ph.D., a Cambridge-trained applied biologist. The company has built a portfolio of 66 issued patents — held jointly with its wholly-owned patent subsidiary Altivera, LLC — covering low-cost, disposable wireless smart skin patches and diagnostic sensors readable by any smartphone via NFC or Bluetooth. Core technology spans skin patches (fever, pain-free diabetes, cardiac, drug delivery, cosmetics), wireless lab-on-a-chip molecular diagnostics, printable battery-less rapid tests, modular e-nose sensors, and the SensorLinker in-home compliance hub. AI is applied in targeted use cases including anomaly detection on cardiac data and biomarker-driven pre-disease detection.

GENTAG's product surface is organized around three licensing markets: IoT sensors, wearables, and advanced diagnostics and pharmaceuticals. Applications include healthcare monitoring, pharmaceutical drug compliance and clinical trial data collection, cosmetics and skin health, food safety, packaging tamper detection, and consumer IoT. The diabetes patch platform is offered for licensing across 28 European countries under European Patent EP1709750, and the company has identified 25 major markets for its patented wireless patches, some of which have been licensed to industry partners.

GENTAG monetizes its portfolio primarily through technology licensing and royalties, supplemented by custom sensor development and hardware sales of the SensorLinker hub. The firm sells exclusively to enterprise licensees and strategic partners rather than to end users, and is open to joint ventures for co-development of specific applications. The company is founder-controlled, with no disclosed institutional investment, and operates with a small team of 11-50 employees led by a science-heavy leadership group that includes a former Director of the US National Science Foundation.

Short descriptiontext

GENTAG is a US private IP and technology development company that licenses patented low-cost disposable wireless smart skin patches and diagnostic sensors readable by any smartphone via NFC or Bluetooth, serving healthcare, pharmaceutical, cosmetics, and consumer IoT licensees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
wearable diagnostic sensors, NFC skin patches, wireless biosensor platforms, smartphone health monitoring, medical wearable devices
Industry3 codes
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYCRABAKAI
Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning)
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
NAICS code2 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Research and Development in Nanotechnology541713
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Wearable Diagnostic Sensors
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

Gentag licenses its patent portfolio covering 66 issued patents to selected companies for use in IoT sensors, wearables, and advanced diagnostics markets. Licensing arrangements cover specific geographic regions (e.g., 28 European countries for diabetes patches). The company is also open to joint ventures.

gentag.com
2Custom Sensor Development
TypeOne Time License
Description

The company develops custom wearable sensors, skin patches, and innovative disposable diagnostic devices for healthcare, consumer, pharmaceutical, and food industries on a custom basis.

gentag.com
3SensorLinker Product Platform
TypeHardware Sales
Description

Customized in-home mobile compliance and diagnostics sensor hub integrating wireless sensors for health providers and pharmaceutical companies.

gentag.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GENTAG develops and licenses low-cost, disposable wireless smart skin patches and biomarker diagnostic devices that deliver medical-grade readings (fever, glucose, cardiac, skin, drug delivery, IoT sensing) directly to any smartphone via NFC or Bluetooth. The company also offers lab-on-a-chip molecular diagnostics, disposable rapid immunoassay tests, modular e-nose chemical sensors, and the SensorLinker in-home compliance hub. Core revenue is generated by licensing its 66-patent portfolio and providing custom sensor development to healthcare, pharmaceutical, consumer, cosmetics, and food-safety partners worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Wireless read ranges from inches to several miles depending on frequency and application
+1 more record
Product overview1 text field

GENTAG offers a portfolio of low-cost, disposable smart skin patches combined with wireless NFC/Bluetooth sensor technology that communicate directly with smartphones for diagnostics and health monitoring. The core platform encompasses skin patches for fever detection, pain-free diabetes monitoring, cardiac monitoring, drug delivery, and cosmetics/skin health. Supporting the patch platform are disposable diagnostic technologies including lab-on-a-chip for molecular analysis, rapid tests for biomarker/allergen/infectious disease detection, and modular e-nose sensors for personalized allergen detection. The SensorLinker hub enables home drug compliance monitoring by aggregating sensor data and transmitting it to healthcare providers. The portfolio spans consumer IoT applications (food safety, cosmetics, consumer goods) and advanced medical diagnostics, all leveraging the company's 66 issued patents covering NFC cell phone sensor networks, wearables, and point-of-care testing technologies.

Product and service1 record
1Fever Patch
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
TypeOthers
Description

Altivera, LLC is Gentag's patent holding company. Together, Gentag, Inc. and Altivera, LLC hold 66 issued patents covering cell phone-based consumer safety sensors, IoT sensors, and sensors for instant diagnostic tests.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Continuous glucose monitoring leader (Dexcom G7) that competes directly with Gentag's pain-free diabetes patch and CGM roadmap in continuous, smartphone-linked glucose sensing.

2Abbott
TypeBroad incumbent
Description

Manufacturer of FreeStyle Libre, the dominant CGM platform and a direct competitor to Gentag's wireless diabetes patch, while also competing in connected diagnostics across its broader device portfolio.

TypeDirect peer
Description

Operates the MiniMed insulin delivery franchise that overlaps Gentag's artificial-pancreas closed-loop insulin delivery patent and competes across diabetes monitoring and drug delivery.

TypeDirect peer
Description

Maker of the Zio wearable cardiac monitor, directly comparable to Gentag's AI-powered cardiac skin patches for ambulatory, smartphone-compatible cardiac monitoring.

TypeEmerging player
Description

Implantable continuous glucose monitoring (Eversense) company pursuing long-duration CGM, a comparable commercial and regulatory bet to Gentag's next-gen pain-free diabetes monitoring IP.

6VitalConnect
TypeDirect peer
Description

Wearable biosensor (VitalPatch) for continuous patient monitoring in hospital and remote settings — directly comparable to Gentag's disposable wireless sensor platform for clinical and RPM use cases.

TypeEmerging player
Description

Developer of intradermal wearable biosensors that, like Gentag's disposable patches, target continuous, minimally invasive metabolite sensing for consumer and clinical use.

8Epicore Biosystems
TypeEmerging player
Description

Sweat-sensing wearable patch company (connected to Gatorade/PepsiCo), highly comparable to Gentag's disposable, smartphone-readable biomarker patches for hydration and skin health.

TypeEmerging player
Description

Builds small wearable devices for continuous health metrics (including glucose, heart rate, blood pressure) that overlap with Gentag's multi-frequency, smartphone-readable wearables.

TypeBroad incumbent
Description

Acquired BioTelemetry to become one of the largest remote cardiac monitoring operators, directly competing with Gentag's wireless cardiac patches for ambulatory ECG and RPM deployment.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GENTAG

Medical Wearable Diagnostic Sensorsgentag.com

GENTAG is a US private IP and technology development company that licenses patented low-cost disposable wireless smart skin patches and diagnostic sensors readable by any smartphone via NFC or Bluetooth, serving healthcare, pharmaceutical, cosmetics, and consumer IoT licensees.

What GENTAG does

GENTAG is a privately held US intellectual-property and technology development company based in Washington, D.C., founded in 1997 by John Peeters, Ph.D., a Cambridge-trained applied biologist. The company has built a portfolio of 66 issued patents — held jointly with its wholly-owned patent subsidiary Altivera, LLC — covering low-cost, disposable wireless smart skin patches and diagnostic sensors readable by any smartphone via NFC or Bluetooth. Core technology spans skin patches (fever, pain-free diabetes, cardiac, drug delivery, cosmetics), wireless lab-on-a-chip molecular diagnostics, printable battery-less rapid tests, modular e-nose sensors, and the SensorLinker in-home compliance hub. AI is applied in targeted use cases including anomaly detection on cardiac data and biomarker-driven pre-disease detection.

GENTAG's product surface is organized around three licensing markets: IoT sensors, wearables, and advanced diagnostics and pharmaceuticals. Applications include healthcare monitoring, pharmaceutical drug compliance and clinical trial data collection, cosmetics and skin health, food safety, packaging tamper detection, and consumer IoT. The diabetes patch platform is offered for licensing across 28 European countries under European Patent EP1709750, and the company has identified 25 major markets for its patented wireless patches, some of which have been licensed to industry partners.

GENTAG monetizes its portfolio primarily through technology licensing and royalties, supplemented by custom sensor development and hardware sales of the SensorLinker hub. The firm sells exclusively to enterprise licensees and strategic partners rather than to end users, and is open to joint ventures for co-development of specific applications. The company is founder-controlled, with no disclosed institutional investment, and operates with a small team of 11-50 employees led by a science-heavy leadership group that includes a former Director of the US National Science Foundation.

GENTAG firmographics

Firmographics
Name
GENTAG
Legal name
GENTAG, Inc.
Website
https://gentag.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
1–10 employees
Short description
GENTAG is a US private IP and technology development company that licenses patented low-cost disposable wireless smart skin patches and diagnostic sensors readable by any smartphone via NFC or Bluetooth, serving healthcare, pharmaceutical, cosmetics, and consumer IoT licensees.
Ownership category
akta.pro rank

GENTAG industry classification

Industry
Product category
Medical Wearable Diagnostic Sensors
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Research and Development in Nanotechnology (541713)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYCRABAKAI
Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning)
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare

Keywords

  • Wearable diagnostic sensors
  • NFC skin patches
  • Wireless biosensor platforms
  • Smartphone health monitoring
  • Medical wearable devices

Where GENTAG is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Markets served

GENTAG business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Technology Licensing: Gentag licenses its patent portfolio covering 66 issued patents to selected companies for use in IoT sensors, wearables, and advanced diagnostics markets. Licensing arrangements cover specific geographic regions (e.g., 28 European countries for diabetes patches). The company is also open to joint ventures.
  2. Custom Sensor Development: The company develops custom wearable sensors, skin patches, and innovative disposable diagnostic devices for healthcare, consumer, pharmaceutical, and food industries on a custom basis.
  3. SensorLinker Product Platform: Customized in-home mobile compliance and diagnostics sensor hub integrating wireless sensors for health providers and pharmaceutical companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

GENTAG product offering

Product offering

Core offering

GENTAG develops and licenses low-cost, disposable wireless smart skin patches and biomarker diagnostic devices that deliver medical-grade readings (fever, glucose, cardiac, skin, drug delivery, IoT sensing) directly to any smartphone via NFC or Bluetooth. The company also offers lab-on-a-chip molecular diagnostics, disposable rapid immunoassay tests, modular e-nose chemical sensors, and the SensorLinker in-home compliance hub. Core revenue is generated by licensing its 66-patent portfolio and providing custom sensor development to healthcare, pharmaceutical, consumer, cosmetics, and food-safety partners worldwide.

Product overview

GENTAG offers a portfolio of low-cost, disposable smart skin patches combined with wireless NFC/Bluetooth sensor technology that communicate directly with smartphones for diagnostics and health monitoring. The core platform encompasses skin patches for fever detection, pain-free diabetes monitoring, cardiac monitoring, drug delivery, and cosmetics/skin health. Supporting the patch platform are disposable diagnostic technologies including lab-on-a-chip for molecular analysis, rapid tests for biomarker/allergen/infectious disease detection, and modular e-nose sensors for personalized allergen detection. The SensorLinker hub enables home drug compliance monitoring by aggregating sensor data and transmitting it to healthcare providers. The portfolio spans consumer IoT applications (food safety, cosmetics, consumer goods) and advanced medical diagnostics, all leveraging the company's 66 issued patents covering NFC cell phone sensor networks, wearables, and point-of-care testing technologies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fever Patch

Quantifiable outcome

  • Wireless read ranges from inches to several miles depending on frequency and application
  • +1 more outcomes

Companies that use GENTAG

Customer profile

Segments4 records

Ideal customer profiles4 records

GENTAG technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

GENTAG partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Altivera, LLCOthersAltivera, LLC is Gentag's patent holding company. Together, Gentag, Inc. and Altivera, LLC hold 66 issued patents covering cell phone-based consumer safety sensors, IoT sensors, and sensors for instant diagnostic tests.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

GENTAG competitors and assessment

Company assessment

Direct peers

  • Dexcom: Continuous glucose monitoring leader (Dexcom G7) that competes directly with Gentag's pain-free diabetes patch and CGM roadmap in continuous, smartphone-linked glucose sensing.
  • Medtronic: Operates the MiniMed insulin delivery franchise that overlaps Gentag's artificial-pancreas closed-loop insulin delivery patent and competes across diabetes monitoring and drug delivery.
  • iRhythm Technologies: Maker of the Zio wearable cardiac monitor, directly comparable to Gentag's AI-powered cardiac skin patches for ambulatory, smartphone-compatible cardiac monitoring.
  • VitalConnect: Wearable biosensor (VitalPatch) for continuous patient monitoring in hospital and remote settings — directly comparable to Gentag's disposable wireless sensor platform for clinical and RPM use cases.

Broad incumbents

  • Abbott: Manufacturer of FreeStyle Libre, the dominant CGM platform and a direct competitor to Gentag's wireless diabetes patch, while also competing in connected diagnostics across its broader device portfolio.
  • Philips (BioTelemetry / Cardiac Monitoring): Acquired BioTelemetry to become one of the largest remote cardiac monitoring operators, directly competing with Gentag's wireless cardiac patches for ambulatory ECG and RPM deployment.

Emerging players

  • Senseonics: Implantable continuous glucose monitoring (Eversense) company pursuing long-duration CGM, a comparable commercial and regulatory bet to Gentag's next-gen pain-free diabetes monitoring IP.
  • Biolinq: Developer of intradermal wearable biosensors that, like Gentag's disposable patches, target continuous, minimally invasive metabolite sensing for consumer and clinical use.
  • Epicore Biosystems: Sweat-sensing wearable patch company (connected to Gatorade/PepsiCo), highly comparable to Gentag's disposable, smartphone-readable biomarker patches for hydration and skin health.
  • Movano Health: Builds small wearable devices for continuous health metrics (including glucose, heart rate, blood pressure) that overlap with Gentag's multi-frequency, smartphone-readable wearables.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

GENTAG social profiles

Digital presence

GENTAG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GENTAG leadership team

Management profile

Number of profiles

Profiles6 records

GENTAG subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

GENTAG funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GENTAG M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GENTAG

What does GENTAG do?

GENTAG develops and licenses low-cost, disposable wireless smart skin patches and biomarker diagnostic devices that deliver medical-grade readings (fever, glucose, cardiac, skin, drug delivery, IoT sensing) directly to any smartphone via NFC or Bluetooth. The company also offers lab-on-a-chip molecular diagnostics, disposable rapid immunoassay tests, modular e-nose chemical sensors, and the SensorLinker in-home compliance hub. Core revenue is generated by licensing its 66-patent portfolio and providing custom sensor development to healthcare, pharmaceutical, consumer, cosmetics, and food-safety partners worldwide.

Is GENTAG a public or private company?

GENTAG is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was GENTAG founded?

GENTAG was founded in 1997. It employs 1 to 10 people.

Where is GENTAG based?

GENTAG is headquartered in Washington, United States, in the North America region.

How does GENTAG make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are custom Sensor Development and sensorLinker Product Platform.

Who are GENTAG's main competitors?

Direct peers on record are Dexcom, Medtronic, iRhythm Technologies and VitalConnect. Broad incumbents are Abbott and Philips (BioTelemetry / Cardiac Monitoring). Emerging players are Senseonics, Biolinq, Epicore Biosystems and Movano Health.

Does GENTAG have an API?

No public API is recorded for GENTAG.

What industry is GENTAG in?

GENTAG's product category is Medical Wearable Diagnostic Sensors. Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring, with a secondary code of CRABAKAI, Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning). Its NAICS code is 3345 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGentag's pathbreaking IP now covers NFC sensors for food and beverage safety, packaging, and counterfeit preventionGentag, Inc. announced the issuance of US patent 10,271,738, covering wireless NFC sensors for detecting bacteria, odors, temperature, chemistry levels, and moisture in food packaging and consumable liquids including spirits. The battery-free sensors feature unique IDs enabling product authentication and tracking, and can be read by any smartphone. The company positions the technology as a solution to the estimated $1.2 trillion in annual global food losses and the projected $5 trillion food and beverages market by 2022.GlobeNewswireCan the IoT Actually Be Secure? These Two Companies Say YesGentag Inc. and Security First Corp. announced an agreement to secure NFC and sensor transactions for IoT applications. Security First's SPx cryptographic splitting technology will protect data for personal identification, payments, healthcare, and fitness. The combined technology is available immediately for market applications.HIT ConsultantMayo Clinic, Gentag Partner to Develop Wearable Biosensors for Obesity and DiabetesMayo Clinic and Gentag, Inc. have partnered to develop wearable biosensors aimed at managing obesity and diabetes, including a wireless disposable patch sensor that communicates via a smartphone platform. The collaboration involves integrating over 50 patents and technologies and aims to create cost-effective, accurate monitoring tools. The partnership intends to potentially reduce global obesity and diabetes rates through advanced health monitoring technology.NFCWNFC medical platform to enable self-testing for pregnancy, fertility, pathogens, Aids, drugs, allergens and certain types of cancersGentag demonstrated an NFC and immunoassay platform enabling self-testing for pregnancy, fertility, pathogens, AIDS, drugs, allergens, and certain cancers. The company licensed the technology to healthcare providers, with mass-market services expected from end of 2011. The platform aims to enable earlier hospital discharge and home self-monitoring.TechCrunchNew Phones Feature: Airborne Pathogen and Bio-Threat Warning SystemGentag has unveiled a concept clamshell phone equipped with a sensor designed to detect airborne biological or chemical threats and alert the user. The device allows owners to select specific pathogens or gases they wish to be warned about, targeting individuals concerned about health risks like asthma or bio-terrorism. Currently, the product remains a concept with no confirmed production timeline or technical specifications.